‘ADOPT’ and ‘DREAM’ trials and the Indian perspective

Buchanan, 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796 Viberti, 2002, A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes, Diabetes Care, 25, 1737, 10.2337/diacare.25.10.1737 Gerstein, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial, Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 Leiter, 2005, Efficacy and safety of rosiglitazone as monotherapy or in combination with metformin in primary care settings, Can J Diabetes, 29, 384 Lebovitz, 2001, Rosiglitazone monotherapy is effective in patients with type 2 diabetes, J Clin Endocrinol Metab, 86, 280, 10.1210/jc.86.1.280 Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–59. Bosch, 2006, Effect of ramipril on the incidence of diabetes, N Engl J Med, 355, 1551, 10.1056/NEJMoa065061 Mohan, 2006, Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India—The Chennai Urban Rural Epidemiology Study (CURES-17), Diabetologia, 49, 1175, 10.1007/s00125-006-0219-2 Mohan, 2003, Glucose intolerance (diabetes and IGT) in a selected south Indian population with special reference to family history, obesity and life style factors—The Chennai Urban Population Study (CUPS 14), J Assoc Phys India, 51, 771 Sadikot, 2004, The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: Prevalence of Diabetes in India Study (PODIS), Diabetes Res Clin Pract, 66, 301, 10.1016/j.diabres.2004.04.008 Mohan, 2005, A simplified Indian diabetes risk score for screening for undiagnosed diabetic subjects, J Assoc Phys India, 53, 759 Mohan, 2007, A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians—The Chennai Urban Rural Epidemiology Study (CURES–38), Diabetes Obes Metab, 9, 337, 10.1111/j.1463-1326.2006.00612.x Ramachandran, 2007, Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India, Diabetes Care, 30, 252, 10.2337/dc06-0144 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 Mohan, 2007, The rosiglitazone controversy: The Indian perspective, J Assoc Physicians India, 55, 477